AGEN

Over the past six months, Agenus's stock price increased by 147.09% as of September 23, 2026. In January 2026, Agenus closed a strategic collaboration with Zydus Lifesciences, securing upfront capital and dedicated manufacturing capacity for its BOT+BAL program. In May 2026, the company reported Q1 2026 financial results, highlighting the execution of its BOT+BAL program and $4.6 million in pre-commercial product revenue. In July 2026, Agenus was in focus due to fresh Phase 1b data on its botensilimab plus balstilimab regimen in refractory microsatellite stable metastatic colorectal cancer and an oversubscribed private placement for its planned ROBBIN Phase 3 trial. In August 2026, Agenus reported Q2 2026 results with revenue of $34.5 million, including $6.4 million in pre-commercial BOT+BAL revenue, and announced peer-reviewed publications linking BOT+BAL's durable survival in MSS metastatic colorectal cancer to its immune-priming mechanism and updated NEST Phase 2 publication reporting deep pathologic responses. In September 2026, Agenus announced it would present three-year overall survival data for BOT+BAL in recurrent ovarian cancer, participate in investor conferences, and received a 'Buy' rating and $40 price target from Chardan, while a director reported beneficial ownership of shares.